Springer Nature
Browse
13063_2022_6791_MOESM2_ESM.pdf (179.84 kB)

Additional file 2 of A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network

Download (179.84 kB)
journal contribution
posted on 2022-10-10, 08:52 authored by Julia M. Neuhann, Jannik Stemler, Antonio Carcas, Jesús Frías-Iniesta, Ullrich Bethe, Sarah Heringer, Lea Tischmann, Marouan Zarrouk, Arnd Cüppers, Franz König, Martin Posch, Oliver A. Cornely
Additional file 2.

Funding

H2020 European Research Council Universitätsklinikum Köln (8977)

History

Usage metrics

    Trials

    Categories

    Keywords

    SARS-CoV-2COVID-19 vaccinationBNT162b2 (Comirnaty®)mRNA-1273 (Spikevax®)Phase IIRandomisationAdvanced age≥75 yearsImmunosenescenceFourth doseBoosterVariants of concernVOC

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC